Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 50 of 409

    1.

    Dual renin-angiotensin system blockade and kidney disease.

    Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Pfeffer MA.

    J Am Coll Cardiol. 2009 Jul 14;54(3):278-9; author reply 279-80. No abstract available. PMID: 19589445 [PubMed - indexed for MEDLINE]Related articles

    2.

    Nephropathy in Fabry disease: the importance of early diagnosis and testing in high-risk populations.

    Oqvist B, Brenner BM, Oliveira JP, Ortiz A, Schaefer R, Svarstad E, Wanner C, Zhang K, Warnock DG.

    Nephrol Dial Transplant. 2009 Jun;24(6):1736-43. Epub 2009 Mar 16. Review. No abstract available. PMID: 19293136 [PubMed - indexed for MEDLINE]Related articles

    3.

    Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.

    Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Ghadanfar M, Weissbach N, Xiang Z, Armbrecht J, Pfeffer MA.

    Nephrol Dial Transplant. 2009 May;24(5):1663-71. Epub 2009 Jan 14.PMID: 19145003 [PubMed - indexed for MEDLINE]Related articles

    4.

    Number of aberrant crypt foci associated with adiposity and IGF1 bioavailability.

    Swede H, Rohan TE, Yu H, Anderson JC, Stevens RG, Brokaw J, Levine J, Brenner BM, Malchoff CD, Duffy VB, Pleau DC, Rosenberg DW.

    Cancer Causes Control. 2009 Jul;20(5):653-61. Epub 2008 Dec 9.PMID: 19067190 [PubMed - indexed for MEDLINE]Related articles

    5.

    Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults.

    Ortiz A, Oliveira JP, Wanner C, Brenner BM, Waldek S, Warnock DG.

    Nat Clin Pract Nephrol. 2008 Jun;4(6):327-36. Epub 2008 Apr 22.PMID: 18431378 [PubMed - indexed for MEDLINE]Related articles

    6.

    Renal risk scores: progress and prospects.

    Taal MW, Brenner BM.

    Kidney Int. 2008 Jun;73(11):1216-9. Epub 2008 Mar 5. Review.PMID: 18322541 [PubMed - indexed for MEDLINE]Related articles

    7.

    ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy.

    Parving HH, de Zeeuw D, Cooper ME, Remuzzi G, Liu N, Lunceford J, Shahinfar S, Wong PH, Lyle PA, Rossing P, Brenner BM.

    J Am Soc Nephrol. 2008 Apr;19(4):771-9. Epub 2008 Jan 16.PMID: 18199798 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Defining renal risk.

    Taal MW, Brenner BM.

    Curr Opin Nephrol Hypertens. 2007 Nov;16(6):554-6. Review. No abstract available. PMID: 18089970 [PubMed - indexed for MEDLINE]Related articles

    9.

    Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study.

    Tershakovec AM, Keane WF, Zhang Z, Lyle PA, Appel GB, McGill JB, Parving HH, Cooper ME, Shahinfar S, Brenner BM.

    Diabetes Care. 2008 Mar;31(3):445-7. Epub 2007 Dec 10.PMID: 18070995 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Fetal programming of adult kidney disease: cellular and molecular mechanisms.

    Hershkovitz D, Burbea Z, Skorecki K, Brenner BM.

    Clin J Am Soc Nephrol. 2007 Mar;2(2):334-42. Epub 2007 Feb 14. Review. No abstract available. PMID: 17699433 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study.

    Keane WF, Zhang Z, Lyle PA, Cooper ME, de Zeeuw D, Grunfeld JP, Lash JP, McGill JB, Mitch WE, Remuzzi G, Shahinfar S, Snapinn SM, Toto R, Brenner BM; RENAAL Study Investigators.

    Clin J Am Soc Nephrol. 2006 Jul;1(4):761-7. Epub 2006 May 17.PMID: 17699284 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.

    Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, Shahinfar S, Gleim GW, Weir MR, Brenner BM, de Zeeuw D.

    J Am Soc Nephrol. 2007 May;18(5):1540-6. Epub 2007 Apr 4.PMID: 17409317 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies.

    Eijkelkamp WB, Zhang Z, Brenner BM, Cooper ME, Devereux RB, Dahlöf B, Ibsen H, Keane WF, Lindholm LH, Olsen MH, Parving HH, Remuzzi G, Shahinfar S, Snapinn SM, Wachtell K, de Zeeuw D.

    J Hypertens. 2007 Apr;25(4):871-6.PMID: 17351381 [PubMed - indexed for MEDLINE]Related articles

    14.

    Allelic losses at genomic instability-associated loci in villous adenomas and adjacent colorectal cancers.

    Brenner BM, Stoler DL, Rodriguez L, Karpenko MJ, Swede H, Petrelli NJ, Anderson GR.

    Cancer Genet Cytogenet. 2007 Apr 1;174(1):9-15.PMID: 17350461 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes.

    Winkelmayer WC, Zhang Z, Shahinfar S, Cooper ME, Avorn J, Brenner BM.

    Diabetes Care. 2006 Oct;29(10):2210-7.PMID: 17003295 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Predicting initiation and progression of chronic kidney disease: Developing renal risk scores.

    Taal MW, Brenner BM.

    Kidney Int. 2006 Nov;70(10):1694-705. Epub 2006 Sep 13. Review.PMID: 16969387 [PubMed - indexed for MEDLINE]Related articles

    17.

    Genomic profiles of colorectal cancers differ based on patient smoking status.

    Swede H, Bartos JD, Chen N, Shaukat A, Dutt SS, McQuaid DA, Natarajan N, Rodriguez-Bigas MA, Nowak NJ, Wiseman SM, Alrawi S, Brenner BM, Petrelli NJ, Cummings KM, Stoler DL, Anderson GR.

    Cancer Genet Cytogenet. 2006 Jul 15;168(2):98-104.PMID: 16843098 [PubMed - indexed for MEDLINE]Related articles

    18.

    Genomic instability of human aberrant crypt foci measured by inter-(simple sequence repeat) PCR and array-CGH.

    Alrawi SJ, Carroll RE, Hill HC, Gibbs JF, Tan D, Brenner BM, Nowak NJ, Swede H, Stoler DL, Anderson GR.

    Mutat Res. 2006 Oct 10;601(1-2):30-8. Epub 2006 Jun 27.PMID: 16806294 [PubMed - indexed for MEDLINE]Related articles

    19.

    The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy.

    Carides GW, Shahinfar S, Dasbach EJ, Keane WF, Gerth WC, Alexander CM, Herman WH, Brenner BM; RENAAL Investigators.

    Pharmacoeconomics. 2006;24(6):549-58.PMID: 16761903 [PubMed - indexed for MEDLINE]Related articles

    20.

    Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL.

    de Zeeuw D, Ramjit D, Zhang Z, Ribeiro AB, Kurokawa K, Lash JP, Chan J, Remuzzi G, Brenner BM, Shahinfar S.

    Kidney Int. 2006 May;69(9):1675-82.PMID: 16572114 [PubMed - indexed for MEDLINE]Related articles

    21.

    Losartan: lessons learned from the RENAAL study.

    Shahinfar S, Lyle PA, Zhang Z, Keane WF, Brenner BM.

    Expert Opin Pharmacother. 2006 Apr;7(5):623-30. Review.PMID: 16553578 [PubMed - indexed for MEDLINE]Related articles

    22.

    Renoprotective effects of renin-angiotensin-system inhibitors.

    de Zeeuw D, Lewis EJ, Remuzzi G, Brenner BM, Cooper ME.

    Lancet. 2006 Mar 18;367(9514):899-900; author reply 900-2. No abstract available. PMID: 16546533 [PubMed - indexed for MEDLINE]Related articles

    23.

    Adult hypertension and kidney disease: the role of fetal programming.

    Zandi-Nejad K, Luyckx VA, Brenner BM.

    Hypertension. 2006 Mar;47(3):502-8. Epub 2006 Jan 16. Review.PMID: 16415374 [PubMed - indexed for MEDLINE]Related articlesFree article

    24.

    'Hypertension' and 'microalbuminuria': the bell tolls for thee.

    Forman JP, Brenner BM.

    Kidney Int. 2006 Jan;69(1):22-8. Review.PMID: 16374419 [PubMed - indexed for MEDLINE]Related articles

    25.

    Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.

    Carr AA, Kowey PR, Devereux RB, Brenner BM, Dahlöf B, Ibsen H, Lindholm LH, Lyle PA, Snapinn SM, Zhang Z, Edelman JM, Shahinfar S.

    Am J Cardiol. 2005 Dec 1;96(11):1530-6. Epub 2005 Oct 17.PMID: 16310435 [PubMed - indexed for MEDLINE]Related articles

    27.

    Primary and secondary prevention of chronic kidney disease.

    Zandi-Nejad K, Brenner BM.

    J Hypertens. 2005 Oct;23(10):1771-6. Review.PMID: 16148593 [PubMed - indexed for MEDLINE]Related articles

    28.

    Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.

    Boner G, Cooper ME, McCarroll K, Brenner BM, de Zeeuw D, Kowey PR, Shahinfar S, Dickson T, Crow RS, Parving HH; RENAAL Investigators.

    Diabetologia. 2005 Oct;48(10):1980-7. Epub 2005 Aug 5.PMID: 16082528 [PubMed - indexed for MEDLINE]Related articles

    29.

    Low birth weight, nephron number, and kidney disease.

    Luyckx VA, Brenner BM.

    Kidney Int Suppl. 2005 Aug;(97):S68-77. Review.PMID: 16014104 [PubMed - indexed for MEDLINE]Related articles

    30.

    Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.

    Zhang Z, Shahinfar S, Keane WF, Ramjit D, Dickson TZ, Gleim GW, Mogensen CE, de Zeeuw D, Brenner BM, Snapinn SM.

    J Am Soc Nephrol. 2005 Jun;16(6):1775-80. Epub 2005 May 4.PMID: 15872078 [PubMed - indexed for MEDLINE]Related articlesFree article

    31.

    Losartan and end-organ protection--lessons from the RENAAL study.

    Kowey PR, Dickson TZ, Zhang Z, Shahinfar S, Brenner BM; RENAAL Investigators.

    Clin Cardiol. 2005 Mar;28(3):136-42.PMID: 15813620 [PubMed - indexed for MEDLINE]Related articles

    32.

    Strategies to retard the progression of chronic kidney disease.

    Zandi-Nejad K, Brenner BM.

    Med Clin North Am. 2005 May;89(3):489-509. Review.PMID: 15755464 [PubMed - indexed for MEDLINE]Related articles

    33.

    Preventing microalbuminuria in type 2 diabetes.

    Zandi-Nejad K, Brenner BM.

    N Engl J Med. 2005 Feb 24;352(8):833-4; author reply 833-4. No abstract available. PMID: 15728819 [PubMed - indexed for MEDLINE]Related articles

    34.

    Baseline predictors of end-stage renal disease risk in patients with type 2 diabetes and nephropathy: new lessons from the RENAAL Study.

    Shahinfar S, Dickson T, Zhang Z, Keane WF, Brenner BM; RENAAL Investigators.

    Kidney Int Suppl. 2005 Jan;(93):S48-51. Review. No abstract available. PMID: 15663528 [PubMed - indexed for MEDLINE]Related articles

    35.

    Poor prognosis in proteinuric type 2 diabetic patients with retinopathy: insights from the RENAAL study.

    Parving HH, Mogensen CE, Thomas MC, Brenner BM, Cooper ME.

    QJM. 2005 Feb;98(2):119-26. Epub 2005 Jan 17.PMID: 15655096 [PubMed - indexed for MEDLINE]Related articlesFree article

    36.

    Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results.

    Remuzzi G, Ruggenenti P, Perna A, Dimitrov BD, de Zeeuw D, Hille DA, Shahinfar S, Carides GW, Brenner BM; RENAAL Study Group.

    J Am Soc Nephrol. 2004 Dec;15(12):3117-25.PMID: 15579515 [PubMed - indexed for MEDLINE]Related articlesFree article

    37.

    From secondary to primary prevention of progressive renal disease: the case for screening for albuminuria.

    de Jong PE, Brenner BM.

    Kidney Int. 2004 Dec;66(6):2109-18. Review.PMID: 15569300 [PubMed - indexed for MEDLINE]Related articles

    38.

    Why is proteinuria an ominous biomarker of progressive kidney disease?

    Zandi-Nejad K, Eddy AA, Glassock RJ, Brenner BM.

    Kidney Int Suppl. 2004 Nov;(92):S76-89. Review.PMID: 15485426 [PubMed - indexed for MEDLINE]Related articles

    39.

    Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy.

    Mohanram A, Zhang Z, Shahinfar S, Keane WF, Brenner BM, Toto RD.

    Kidney Int. 2004 Sep;66(3):1131-8.PMID: 15327408 [PubMed - indexed for MEDLINE]Related articles

    40.

    Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.

    de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM.

    Circulation. 2004 Aug 24;110(8):921-7. Epub 2004 Aug 9.PMID: 15302780 [PubMed - indexed for MEDLINE]Related articlesFree article

    41.

    The renoprotective effects of structured care in a clinical trial setting in type 2 diabetic patients with nephropathy.

    Leung WY, So WY, Tong PC, Lo MK, Lee KF, Ko GT, Chan WB, Cockram CS, Brenner BM, Shahinfar S, Critchley JA, Chan JC.

    Nephrol Dial Transplant. 2004 Oct;19(10):2519-25. Epub 2004 Jul 27.PMID: 15280527 [PubMed - indexed for MEDLINE]Related articlesFree article

    42.

    Renoprotection by enzyme replacement therapy.

    Brenner BM, Grünfeld JP.

    Curr Opin Nephrol Hypertens. 2004 Mar;13(2):231-41. Review. No abstract available. PMID: 15202618 [PubMed - indexed for MEDLINE]Related articles

    43.

    Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

    de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM.

    Kidney Int. 2004 Jun;65(6):2309-20.PMID: 15149345 [PubMed - indexed for MEDLINE]Related articles

    44.

    Regarding: "Management of glomerular proteinuria: a commentary".

    Brenner BM.

    J Am Soc Nephrol. 2004 May;15(5):1354-5; discussion 1356-7. Review. No abstract available. PMID: 15100378 [PubMed - indexed for MEDLINE]Related articlesFree article

    45.

    Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL Study.

    Chan JC, Wat NM, So WY, Lam KS, Chua CT, Wong KS, Morad Z, Dickson TZ, Hille D, Zhang Z, Cooper ME, Shahinfar S, Brenner BM, Kurokawa K; Asian RENAAL Study Investigators.

    Diabetes Care. 2004 Apr;27(4):874-9.PMID: 15047641 [PubMed - indexed for MEDLINE]Related articlesFree article

    46.

    Impact of renin angiotensin system blockade on renal function in health and disease: an end or a beginning?

    Abdi R, Brenner BM.

    Semin Nephrol. 2004 Mar;24(2):141-6. Review.PMID: 15017526 [PubMed - indexed for MEDLINE]Related articles

    47.

    Impact of the supplementation of kidney mass on blood pressure and progression of kidney disease.

    Ots M, Troy JL, Rennke HG, Mackenzie HS, Brenner BM.

    Nephrol Dial Transplant. 2004 Feb;19(2):337-41.PMID: 14736956 [PubMed - indexed for MEDLINE]Related articlesFree article

    48.

    Gallbladder cancer gene hypermethylation: genetics or environment?

    Pitt HA, Brenner BM.

    Ann Surg Oncol. 2003 Oct;10(8):832-3. No abstract available. PMID: 14527898 [PubMed - indexed for MEDLINE]Related articles

    49.

    AMGEN International Prize: the history and future of renoprotection.

    Brenner BM.

    Kidney Int. 2003 Oct;64(4):1163-8. Review. No abstract available. PMID: 12969133 [PubMed - indexed for MEDLINE]Related articles

    50.

    Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors.

    Brenner BM, Zagrobelny J.

    Kidney Int Suppl. 2003 Feb;(83):S77-85. Review.PMID: 12864880 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Find related data

    Search details

    » See more...